Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycle

Journal of Infectious Diseases

Volumn 199, Issue 3, 2009, Pages 455-463

  Safaeian, Mahboobeh ^a   Falk, Roni T ^a   Rodriguez, Ana Cecilia ^a,c   Hildesheim, Allan ^a   Kemp, Troy ^b   Williams, Marcus ^b   Morera, Lidiana ^c   Barrantes, Manuel ^c   Herrero, Rolando ^c   Porras, Carolina ^c   Pinto, Ligia ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BEHAVIOR; BLOOD; BLOOD SAMPLING; CYCLING; DEMOGRAPHY; FEMALE; FOLLICULAR PHASE; HUMAN; LIFESPAN; LUTEAL PHASE; MENSTRUAL CYCLE; OVARY CYCLE; PREGNANCY; PRIORITY JOURNAL; QUESTIONNAIRE; UTERINE CERVIX; UTERINE CERVIX MUCUS; WEIGHT;

ADULT; CERVIX UTERI; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MENSTRUAL CYCLE;

EID: 58849140953     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596060     Document Type: Article

References (22)

1. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
2. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65.
3. Stanley M, Lowy DR, Frazer I. Chapter 12. Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24(Suppl 3):S106-13.
4. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hartmann F, Degrandi P. Antibody responses in cervical secretions of female volunteers after intramuscular vaccination with purified HPV16 VLPs [abstract]. In: Program and abstracts of the 19th International Papillomavirus Conference (Florianopolis, Brazil). 2001.
5. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95:1128-37.
6. Bratti MC, Rodriguez AC, Schiffman M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica 2004; 15:75-89.
7. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997; 1:362-75.
8. Castle PE, Rodriguez AC, Bowman FP, et al. Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. Clin Diagn Lab Immunol 2004; 11:399-405.
9. Hamelinck D, Zhou H, Li L, et al. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics 2005; 4:773-84.
10. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
11. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24:5571-83.
12. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49.
13. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116:1167-73.
14. Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999; 42:93-106.
15. Wira CR, Stern JE. Estradiol regulation of the secretory immune system in the female reproductive tract: IgA in uterine and vaginal secretions of rats following portacaval anastomosis. J Steroid Biochem 1986; 24:33-7.
16. Hildesheim A, McShane LM, Schiffman M, et al. Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. J Immunol Methods 1999; 225:131-43.
17. Kutteh WH, Franklin RD. Quantification of immunoglobulins and cytokines in human cervical mucus during each trimester of pregnancy. Am J Obstet Gynecol 2001; 184:865-72.
18. Eissa MK, Sparks RA, Newton JR. Immunoglobulin levels in the serum and cervical mucus of tailed copper IUD users. Contraception 1985; 32:87-95.
19. Jonsson B, Landgren BM, Eneroth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991; 43:447-58.
20. Makhlouf H, bou-gabal A, El-hefnawi N, Khalifa A. Immunoglobulin levels in the cervical mucus of copper intrauterine contraceptive device users. Popul Sci 1988; 8:19-29.
21. Wollen AL, Sandvei R, Mork S, Marandon JL, Matre R. In situ characterization of leukocytes in the fallopian tube in women with or without an intrauterine contraceptive device. Acta Obstet Gynecol Scand 1994; 73:103-12.
22. Gravitt PE, Hildesheim A, Herrero R, et al. Correlates of IL-10 and IL-12 concentrations in cervical secretions. J Clin Immunol 2003; 23:175-83.